Research To Practice | Oncology Videos

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after completing olaparib/bevacizumab maintenance therapy — Professor Jonathan A Ledermann (0:00) CME informa...

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics: Introduction (0:00) New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20) Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33) Potential Role of C...

Featuring perspectives from Dr Sara M Tolaney, including the following topics: Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00) Managing brain metastases in triple-negative breast cancer (6:30) EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11) PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC...

Featuring perspectives from Dr Sara M Tolaney, including the following topics: Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00) First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13) First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02) Antibody-drug conjugates for pre...

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics: Introduction (0:00) Minimal Residual Disease Assays in Community-Based Practice (1:24) New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12) Richter Transformation (30:43) Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (3...

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal cuff brachytherapy — Dr Angeles Alvarez Secord (0:00) Case: A woman in her mid 50s with ovaria...

Featuring an interview with Dr L Elizabeth Budde, including the following topics: Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00) Management of BsAb-induced cytokine release syndrome and other toxicities (7:35) Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSu...

Featuring a slide presentation and related discussion from Dr L Elizabeth Budde , including the following topics: Overview of approved and investigational CD20 x CD3 bispecific antibodies (BsAbs) in non-Hodgkin lymphoma; key findings from Phase II studies evaluating glofitamab and epcoritamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (0:00) Bringing BsAbs into earlier-line setting...

Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) EGFR Mutations (2:23) HER2 Alterations (22:40) Available and Investigational Immunotherapies (32:14) Small Cell Lung Cancer (40:48) CME information and select publications

Featuring an interview with Dr Neeraj Agarwal, including the following topics: Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00) Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13) Potential usage of capivasertib as second-line therapy for metastatic androgen pathway...

Featuring a slide presentation and related discussion from Dr Neeraj Agarwal , including the following topics: Therapeutic targets of systemic therapy in prostate cancer (0:00) Prevalence of genomic alterations in prostate cancer including PTEN deficiency; prognostic and predictive value (3:52) Optimal timing of and approach to PTEN assessment; pathophysiology surrounding PTEN loss (9:29) Comparis...

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment (1:33) Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36) CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00) Commentary: Role of HER2-direc...

Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) Ovarian Cancer (2:22) Endometrial Cancer (37:48) CME information and select publications

Featuring an interview with Dr Alexander E Drilon, including the following topics: Overview of targetable biomarkers in lung cancer (0:00) Biomarker testing for genomic alterations in lung cancer (5:24) Overview of ROS1 alterations in lung cancer (13:44) Efficacy data with ROS1 inhibitors for lung cancer (17:02) Safety data with ROS1 inhibitors for lung cancer (21:15) Case: A woman in her early 50...

Featuring an interview with Professor Nicoletta Colombo, including the following topics: Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00) Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31) Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian c...

Featuring a slide presentation and related discussion from Professor Nicoletta Colombo , including the following topics: Rationale for targeting the glucocorticoid receptor; relacorilant mechanism of action (0:00) Key efficacy and safety findings from a Phase II study of relacorilant/nab paclitaxel for platinum-ineligible ovarian cancer (3:09) Key findings from the Phase III ROSELLA study (7:06) C...

Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48) Management of HER2-Positive Gastroesophageal Cancer (25:11) Neoadjuvant Therapy for Gastroesophageal Cancer (45:13) Note to listeners: Subsequent to the recording of this symposiu...

Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Therapy (2:48) Relapsed/Refractory Disease (39:30) CME information and select publications

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics: Introduction (0:00) Trials in Progress (1:12) Chronic Lymphocytic Leukemia (7:09) Diffuse Large B-Cell Lymphoma (32:35) Mantle Cell Lymphoma (58:25) Follicular Lymphoma (1:14:49) CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic: Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A Ledermann CME information and select publicatio...

Featuring a slide presentation and related discussion from Dr Douglas W Sborov, including the following topics: Overview of the treatment landscape for early relapsed multiple myeloma (MM) (0:00) Belantamab mafodotin (belamaf) mechanism of action and Phase II DREAMM-2 study of belamaf monotherapy in heavily pretreated MM (6:20) DREAMM-7 and DREAMM-8 Phase III trials of belamaf combination strategi...

Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for r...

Featuring perspectives from Dr David W Cescon, including the following topics: Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00) CNS activity of TROP2-directed antibody-drug conjugates (5:36) Autoimmune considerations with immunotherapy (10:09) Treatment of oligoprogressive advanced breast cancer (17:31) CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics: First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00) First-line treatment of mTNBC in patients eligible for immunotherapy (12:05) Adverse events (19:39) CME information and select publications